130,000 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Iron Triangle Partners LP

Iron Triangle Partners LP purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 130,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $16,140,000. Jazz Pharmaceuticals accounts for 2.6% of Iron Triangle Partners LP’s investment portfolio, making the stock its 21st largest holding.

A number of other institutional investors have also recently modified their holdings of the stock. Versant Capital Management Inc boosted its position in shares of Jazz Pharmaceuticals by 9.4% during the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 91 shares during the last quarter. Kendall Capital Management boosted its position in shares of Jazz Pharmaceuticals by 1.2% during the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock valued at $989,000 after buying an additional 95 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Jazz Pharmaceuticals by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock valued at $2,098,000 after buying an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its position in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company’s stock valued at $1,046,000 after buying an additional 110 shares during the last quarter. Finally, Cardinal Capital Management boosted its position in shares of Jazz Pharmaceuticals by 0.9% during the first quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company’s stock valued at $1,645,000 after buying an additional 114 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 1.4%

NASDAQ JAZZ opened at $126.13 on Friday. The stock’s 50-day moving average price is $114.07 and its 200-day moving average price is $117.25. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a market capitalization of $7.65 billion, a P/E ratio of -18.74, a price-to-earnings-growth ratio of 7.84 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the business earned $5.30 EPS. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company’s stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 target price on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.21.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.